Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Gonzalez Lengua

Cardiovascular Disease Jackson Heights, NY Medical Doctor

NPI 1568732451 CMS profile 4209891

3722 82Nd St Fl 2, Jackson Heights, NY 11372

Open in the dashboard

General payments

$55,745

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Gonzalez Lengua of Jackson Heights, NY is reported in the CMS Open Payments database as having received $55,745 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,502 76
2024 General $8,480 63
2023 General $10,730 60
2022 General $4,413 53
2021 General $1,514 31
2020 General $1,036 17
2019 General $21,072 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Gonzalez Lengua
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Carlos Gonzalez Lengua were reported at $8,502. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Carlos Gonzalez Lengua Cardiovascular Disease median Middle half National median
2019 $21,072 $450 $127–$1,392 $163
2020 $1,036 $242 $77–$751 $114
2021 $1,514 $335 $101–$1,037 $132
2022 $4,413 $395 $121–$1,211 $149
2023 $10,730 $443 $136–$1,283 $160
2024 $8,480 $450 $136–$1,323 $164
2025 $8,502 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $18,530 5 payments
  2. Medtronic, Inc. $12,668 51 payments
  3. Edwards Lifesciences Corporation $8,059 26 payments
  4. Abbott Laboratories $5,901 68 payments
  5. Boston Scientific Corporation $4,742 73 payments
  6. Penumbra, Inc. $1,984 18 payments
  7. Abiomed $1,253 20 payments
  8. W. L. Gore & Associates, Inc. $469 8 payments
  9. Philips Electronics North America Corporation $450 4 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $294 9 payments
  11. Other $1,397 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $18,055 2 payments
  2. Food and Beverage $14,958 281 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,128 12 payments
  4. Consulting Fee $5,830 4 payments
  5. Travel and Lodging $5,585 25 payments
  6. Education $190 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $12,265 36 payments
  2. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $5,546 6 payments
  3. Indigo System $1,960 17 payments
  4. MITRACLIP $1,884 17 payments
  5. TRICLIP $1,743 14 payments
  6. WATCHMAN Access System $1,477 12 payments
  7. WATCHMAN FLX $1,013 19 payments
  8. Impella $860 13 payments
  9. SAPIEN 3 Ultra RESILIA $758 15 payments
  10. AMPLATZER AMULET $592 14 payments
  11. Other $7,787 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

43

Median for Interventional Cardiology: 2,236

Drug cost

$762

Median for Interventional Cardiology: $380,412

Branded share of claims

100%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 43 $762

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$227,546

Medicare's payments for the services billed

Medicare patients

423

Average age 78

Services billed

1,435

153 women, 270 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 63%
Atrial fibrillation 56%
Heart failure 51%
Chronic kidney disease 47%
Diabetes 39%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record